Nyrada Inc (ASX:NYR) Share Price

Company Profile

Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUS
T: +61 294983390
https://www.nyrada.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,157.74	31.21	0.38%
DAX 40	24,663.30	124.49	0.51%
Dow JONES (US)	48,892.47	179.09	-0.36%
FTSE 100	10,250.60	27.06	0.26%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,461.82	223.30	-0.94%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,412.44	10.74	-0.08%
S&P 500	6,939.03	29.98	-0.43%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%